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To determine clinical and structural imaging predictors of impulsive 
compulsive behavior (ICB) in de-novo Parkinson’s disease (PD). 
Methods 
From a cohort of 1116 subjects from the Parkinson’s Progression Marker 
Initiative database, we created a sub-cohort of 42 de novo PD without ICB at 
baseline with available 3T MRI and who developed ICB during follow-up. PD-
ICB were matched for age, gender and disease duration to 42 PD patients 
without ICB over follow-up (PD-no-ICB) and 42 healthy controls (HC). 
Baseline demographic and clinical predictors of ICB were analyzed. For the 
longitudinal neuroimaging analysis, we selected 27 PD-ICB patients with 
available neuroimaging after ICB onset, who were matched with 32 PD-no-
ICB and 35 HC. Baseline and longitudinal structural differences were 
compared using voxel-based morphometry and voxel-based quantification. 
Results 
People who went on to develop ICB had more severe anxiety, worse 
autonomic and global cognitive functions and were more likely to have RBD. 
Logistic regression confirmed that worse autonomic and cognitive functions 
were predictors of ICB. We could not find any morphological feature on 
baseline MRI that predicted later onset of ICB. When comparing PD groups at 
follow-up, a small region of increased atrophy in the anterior limb of the left 
internal capsule adjacent to the head of the left caudate nucleus was found in 
PD-ICB, but not surviving correction for multiple comparisons. 
Conclusions 
Worse autonomic and cognitive functions predict development of ICB at the 
time of PD diagnosis. Structural imaging fails to identify morphological 







Impulsive compulsive behaviors (ICB) are disabling neuropsychiatric 
disturbances occurring in up to 30% of Parkinson’s disease (PD) patients. 
They include impulse control disorders (ICD) such as pathological gambling, 
hypersexuality, compulsive buying and binge eating, and compulsive 
behaviors such as punding and compulsive use of dopamine replacement 
therapy (also known as dopamine dysregulation syndrome)1. The 
pathophysiological basis is unconfirmed, but it is likely that ICB are not simply 
drug-induced phenomena2. Predisposing cognitive profiles have been 
reported in some cross-sectional studies, but not confirmed by others3-5. A 
novelty seeking personality profile, higher impulsivity6, impairment in sense of 
agency7,more severe depression8 and anhedonia9 have been associated with 
ICB. Genotype may also be a predisposing factor, as PD associated with the 
Parkin mutation have more severe ICB10. Functional11 and structural cross-
sectional neuroimaging studies12-14 have reported a number of abnormalities 
in the fronto-striatal circuit and in the limbic areas. Only one previous study 
has looked for predictors of later development of ICB by analyzing 
demographic, motor symptom scores and dopamine transporter imaging data 
from the  Parkinson Progressive Markers Initiative (PPMI) cohort of de novo 
PD patients15. However, the potential predictive value of non-motor symptom 
assessment and structural neuroimaging has not yet been explored.   
In the present study, we aimed to evaluate in a de novo PD population from 
the PPMI cohort: 1) whether there are motor or non-motor features predicting 
later onset of ICB at the time of PD diagnosis; 2) whether there are any 
structural MRI abnormalities at baseline or follow-up that can predict later 
onset of ICB.  
METHODS 
Subjects 
Data were obtained from the PPMI database (http://www.ppmi-info.org/data). 
The aims and methodology of this database have been previously 
published16, and are available through the PPMI website (http://www.ppmi-
info.org/study-design). At the time we acquired the data for this work 
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(downloaded 29th November 2015), 1116 participants had been included in 
the study.  
We searched the database for de novo PD patients not receiving any 
dopaminergic treatment who screened negative for ICB at baseline visit and 
converted to positive screening at any study time at follow-up according to the 
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
(QUIP)17.  The PPMI is a large multicenter study, and consequently a mixture 
of different MRI acquisitions and field strengths have been used in the 
generation of the imaging dataset. To simplify the analysis and remove a 
major potential source of non-experimental error, we elected to create a 
homogenous MRI dataset for this work by selecting only those participants 
who had undergone 3T MRI scanning and had a T1 MPRAGE acquisition at 
baseline. Through this process, we identified 42 PD patients converting to ICB 
(PD-ICB). We matched these patients by age, gender and disease duration 
with 42 PD patients who did not develop ICB at follow-up (PD-no-ICB) and  42 
healthy controls matched by age and gender who had no ICB. These two 
groups were compared for the baseline clinical and neuroimaging variables at 
baseline for the cross-sectional analysis.  
For the longitudinal analysis, from our group of 42 PD-ICB patients, we 
included 29 who had the requisite imaging after ICB onset. We acquired the 
MRI data using the closest time-point following onset of ICB. Two datasets 
were excluded due to severe movement artifact that prevented pre-
processing, leaving 27 subjects in the longitudinal PD-ICB group. For 
comparison, we also identified the corresponding longitudinal imaging for PD-
no-ICB (n=32) and HC (n=35), selecting the time-points to match the ICB 
group as closely as possible. Figure 1 illustrates the selection process.  
Clinical assessment 
The presence of ICB was investigated in PD and HC by means of the QUIP17.  
The QUIP is designed as a screening instrument for ICB, based on any single 
positive response for the four major ICBs (gambling, eating, buying, sexual 
behaviours), hobbyism, simple motor activities (i.e., punding). A positive 




Demographic (age, gender, level of education) and clinical data were 
considered in HC and in both groups of PD patients at baseline evaluation, 
before starting dopaminergic treatment. The following rating scales were 
assessed at baseline visit in HC and PD:  Geriatric depression scale (GDS) 
and State-trait anxiety inventory (STAI). Autonomic function was rated by the 
Scales for Outcomes in Parkinson's disease – Autonomic (SCOPA-AUT) and 
olfaction by the University of Pennsylvania Smell Identification Test (UPSIT).  
The REM Sleep Behavior Disorder Questionnaire (RBDSQ)18 was employed 
to reach the diagnosis of Rapid Eye Movement Sleep Behavior disorder 
(RBD); the RBDSQ revealed a specificity of 92% when using a cut-off value of 
5. Overall cognitive function was evaluated by means of the Montreal 
cognitive assessment (MoCA) and specific cognitive domains were assessed 
as it follows: episodic verbal memory by Hopkins verbal learning test – 
revised; visuo-spatial functions by Benton judgment of line orientation; 
attention and executive functions by Letter number sequencing, Symbol digit 
modalities test (SDMT), phonological fluency; language by semantic fluency. 
In the PD group, disease severity and disability were rated by means of the 
Movement Disorders Society Unified Parkinson’s Disease Rating Scale 
(MDS-UPDRS)] part III and the Modified Schwab & England Activities of Daily 
Living. Dopaminergic treatment was expressed in terms of total Levodopa 
Equivalent Daily Dose (LEDD) and dopamine-agonists (D-Ag) LEDD. We 
selected the LEDD either at the time of QUIP conversion from negative to 
positive in PD-ICB, or at the last available follow-up visit for those remaining 
QUIP-negative (PD-no-ICB). 
Pre-Processing - All 
The raw DICOMS were downloaded from the PPMI website. These were 
imported using SPM12 software package 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). Each image was manually 
checked to ensure a common orientation and origin. These varied 
significantly, and manual realignment in SPM12 was required for some of the 
datasets to ensure they all were reasonably close to MNI orientation prior to 
the automated re-alignment pipelines. The original image resolution was 
between 1mm and 1.1mm isotropic.  All available MRI data was then re-
aligned to MNI orientation and re-sliced to 1mm isotropic voxel resolution in 
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subject space using 4th degree b-spline interpolation. All re-orientated T1 
weighted images were then segmented into grey, white and CSF tissue 
classes19. These segmentations were used to generate cortical thickness 
maps using the VBCT toolbox 20 in SPM8 (this toolbox is currently 
incompatible with SPM12) with a sampling resolution of 0.5mm, CSF 
smoothness 3mm, CSF thinness 0.65 and number of dilations was set to 1.  
Pre-Processing - Baseline 
The baseline GM, WM and CSF segmentations were then used to generate a 
group average template using the diffeomorphic warping “Shoot” algorithm in 
SPM1221. The segmentations were then warped using the resulting 
deformation fields, modulated with the Jacobian determinant data and 
smoothed with a 6mm full width half maximum (FWHM) Gaussian kernel. The 
CT maps were also warped using the corresponding deformation fields. The 
warped CT maps were then used to generate FWHM 6mm smoothed warped 
weighted images22. These warped weighted images avoid the parameter 
value changes caused by the necessary Gaussian smoothing in standardised 
space. Total intracranial volume (TIV) was calculated by integrating the 
Jacobians within the three tissue classes, with the segmentations binarised at 
a threshold of 0.2.  
Pre-Processing - Longitudinal 
Using the “Longitudinal Registration” toolbox in SPM1223, the paired 
longitudinal T1 weighted images were registered together using pairwise 
longitudinal registration. This produced Jacobian determinant, warp fields and 
divergence maps for each time-point in addition to the individual average 
image that is the midpoint between the two time points. The divergence maps 
quantify the diffeomorphic distance between the subject time-point image from 
the average image, and represent the rate of expansion or contraction 
required to warp it to the average image. For the cortical thickness, these 
were warped to the individual midpoint (using the calculated warp fields from 
pairwise longitudinal registration), and a voxel-wise linear fit used to calculate 
the rate of CT change between the two. The midpoint T1 images were then 
segmented GM, WM and CSF, and used to generate a longitudinal group 
average space using the diffeomorphic warping “Shoot” algorithm. All rate 
maps (already in individual average space) were then warped to this 
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longitudinal group average space. To statistically analyze the tissue specific 
rate maps, a voxel based quantification (VBQ) approach was adopted as 
previously described22. Specifically, the rate maps for GM, WM and CT were 
treated as parameter maps, and the combined weighting/smoothing 
procedure used to generate WWA rate-maps using a 6mm full width at half 
maximum (FWHM) Gaussian kernel. 
 
STATISTICAL ANALYSIS 
Two-group comparisons (PD vs HC; PD-ICB vs PD-no-ICB) were computed 
for all demographic, psychiatric, cognitive, sleep and olfaction data by means 
of the Mann-Whitney U test. Spearman bivariate correlations analysis was 
used to investigate possible correlation between clinical variables and 
psychiatric, cognitive, sleep and olfaction scores in each group and in the PD 
group as a whole. Binary logistic regression was used to test the association 
between development of ICB (presence/absence as dependent variable) and 
the following variables at baseline visit as regressors: age, MOCA, RBD 
(yes/no), autonomic dysfunction (as per SCOPA-AUT) and anxiety (by STAI). 
For the MRI data, all analysis was performed in SPM12. All group analysis 
was performed in the population group average space. The baseline VBM 
analysis used the baseline warped modulated GM and WM. The baseline 
VBQ analysis used the baseline WWA CT maps. The longitudinal rate 
analysis used the longitudinal WWA GM, WM and CT rate maps. All analysis 
used an ANOVA in SPM, including age, total intracranial volume and gender 
as confounding variables. The principal comparisons of interest were PD (ICB 
and no-ICB) versus HC, and ICB-PD versus no-ICB-PD. In all statistical 
analyses the regions that survived Family Wise Error (FWE) multiple 
comparison correction at p < 0.05 were considered significant. All significant 
results are displayed at both p < 0.001 uncorrected and FWE corrected p < 
0.05. The legends are labeled accordingly. All data are given as mean ± 





Clinical and MRI data at baseline 
Tables 1 and 2 show demographical and clinical data comparisons between 
HC and PD and PD-ICB and PD-no-ICB at the time of baseline evaluation. PD 
patients differed from HC by severity of anxiety, depression, olfaction 
impairment and autonomic dysfunction, respectively by STAI, GDS, UPSIT 
and SCOPA-AUT; moreover, PD were more likely to have RBD and worse 
phonological fluency (table 1).  
When considering the two PD groups, disease duration, motor symptom 
severity (as per MDS-UPDRS III) and cognitive measures were comparable, 
except for a lower MOCA score in PD-ICB (table 2). PD patients who later 
developed ICB were more anxious (p=0.02 for STAI-state, 0.01 for STAI-trait 
and p=0.009 for STAI total score), had worse autonomic impairment (as per 
SCOPA-AUT, p=0.004) and were more likely to have RBD (p=0.03) compared 
to PD patients who remained free of ICB at follow-up. Binary logistic 
regression analysis showed that only MOCA score and autonomic function as 
measured by the SCOPA-AUT were significant baseline predictors of later 
development of ICB (table 3). 
At baseline (de novo PD vs HC) we found no differences between HC and PD 
(FWE P < 0.05) and PD-no-ICB and PD-ICB (FWE P < 0.05) in any of the 
analyses (GM and WM VBM, cortical thickness VBQ). 
 
Clinical and MRI data at follow-up  
Disease duration was shorter in PD-ICB compared to PD-no-ICB (table 2) at 
the time of follow-up. Mean latency time between start of dopaminergic 
treatment and onset of ICB was 14.48.8 months; 11 out of 42 PD-ICB 
patients (26%) were not taking anti-parkinsonian medications at the time of 
ICB onset. All other PD-ICB patients were treated with levodopa (n=6), 
dopamine-agonists (n=7), other dopamine replacement therapies (n=6), or a 
combination of the above treatments (n=12). PD-ICB patients had lower total 
LEDD driven by a significantly lower dose of Levodopa compared to PD-no-
ICB, but the two groups did not differ by D-Ag LEDD at last follow-up.  
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PD groups were matched by disease duration at the time they received the 
second MRI scan (PD-ICB=23.60 ± 8.87 months; PD-no-ICB=22.61 ± 4.83 
months (p = 0.59). There was a faster rate of grey and white matter atrophy, 
particularly bilateral hippocampi and striatum, in those with PD compared to 
HC (FWE P < 0.05).The average annualized rate of atrophy and thresholded 
t-statistic maps are shown in Figure 2, with FWE P<0.05 and uncorrected P < 
0.001 labeled accordingly. No differences (FWE P < 0.05) were observed in 
atrophy rate of grey matter, white matter and cortical thickness between PD-
ICB and PD-no-ICB. Given previous reports of focal atrophy in PD patients 
with ICB12 14, we explored the data with a more lenient statistical threshold 
(uncorrected P < 0.001) which revealed a small region of increased atrophy 
rate in the anterior limb of the left internal capsule adjacent to the head of the 
left caudate nucleus (Figure 3). 
DISCUSSION 
Impulsive-compulsive behaviors are a common and disabling feature of 
Parkinson’s disease, whose main risk factor is use of dopaminergic drug, 
particularly dopamine-agonists24. The knowledge of clinical and structural 
imaging features able to predict their later development in newly diagnosed 
patients would likely improve clinical management and outcome.   
Previous clinical6 25-27 and neuroimaging studies11-14 have provided potential 
insights, but they had a cross-sectional design and were performed in patients 
with advanced PD. Higher anxiety levels6 25 and presence of RBD have been 
associated with an increased risk of developing ICB in PD patients with long 
disease duration 26 27.  In our study, the strongest predictors of impulsive-
compulsive behaviors were worse cognitive and autonomic function, and level 
of anxiety and presence of RBD did not survive logistic regression analysis.  
The role of cognitive dysfunction as a risk factor for impulsive-compulsive 
behavior is controversial. In our cohort, patients with ICB had lower MOCA 
scores compared to those without ICB, but the two groups did not differ by 
any of the specific cognitive domains tested at baseline.  A recent longitudinal 
study analyzing a sample of PD patients with a long disease duration, 
demonstrated better scores on MMSE, semantic fluency and attentional 
matrices tasks in patients with ICB compared to PD-no-ICB28.  However, sub-
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group analysis of those who did not have remission of ICB after dopamine-
agonist withdrawal showed cognitive scores comparable to PD-no-ICB. In 
addition, a recent meta-analysis of 34 cross-sectional studies found a 
significant relationship between ICB and dysfunction in specific cognitive 
domains 29.  
The finding of more severe autonomic dysfunction in those patients who later 
developed ICB is novel and has not been described in cross-sectional studies. 
Interestingly, autonomic dysfunction is associated with reduced amygdala 
grey matter volume30, an area which has been proposed as part of the 
anatomical substrate of ICB24.  However, the lower SCOPA-AUT scores in 
patients with impulsive-compulsive behaviors might be explained by loss of 
peripheral sympathetic or parasympathetic nerve terminals31. Regardless of 
the site of autonomic dysfunction, this association might suggest a more 
severe clinical phenotype of the disease in PD with impulsive-compulsive 
behavior. Dysautonomia may predict worse disease progression in early PD 
32 and lower MOCA score and RBD at the time of PD diagnosis have been 
found as predictive factors of mild cognitive impairment33. 
 In our cohort, 26% of patients developed ICB following their baseline 
assessment without being exposed to any dopaminergic medication. This is 
quite a remarkable finding and provides further evidence against the 
prevailing view that ICB in PD are a pure medication-induced phenomena8. 
Our data instead support the hypothesis that disease-intrinsic factors are 
involved alongside dopaminergic medication in the pathogenesis of ICB. 
Indeed, it is important to note that our cohort of patients who developed ICB 
had comparable dopamine agonist dose, lower levodopa dose and shorter 
disease duration than the cohort without ICB. Therefore they appear to be 
prone to develop behavioral disturbances in an earlier phase of the disease 
and with a lower dose of dopaminergic therapy. A lower dose of dopaminergic 
treatment has been also associated with more frequent and severe ICB in PD 
patients carrying the Parkin mutation, with some also developing it before 
medication use10. 
Following the hypothesis that ICB might be underlined by disease-intrinsic 
factors in PD, we looked for structural predictors of ICB on brain MRI. 
Previous cross-sectional studies revealed an increased cortical thickness of 
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limbic regions13 14 and thinning of the fronto-striatal regions12 in PD-ICB. 
Moreover, brain metabolism and functional imaging studies have shown 
abnormalities in the fronto-striatal circuit and in the limbic areas such as the 
orbito-frontal cortex, anterior cingulate cortex, amygdala, nucleus accumbens 
in patients with advanced PD and ICB11. However, these studies had a cross-
sectional design and it was unknown if these abnormalities were present at 
baseline in patients destined to develop ICB. Our study suggests that they are 
not, as we found no structural difference at baseline or longitudinally between 
PD-ICB and PD-no-ICB in our analysis. The increased grey and white matter 
atrophy in PD compared to healthy controls in our longitudinal analysis 
indicates that the imaging methods we used were sufficiently sensitive to 
detect changes in this cohort. The lack of any baseline structural predictor of 
ICB is in keeping with a recent study analyzing DAT binding in new incident 
ICB patients from the PPMI cohort15. DAT binding was unable to predict 
incident ICB, even when controlling for LEDD which is a main confounder of 
DAT studies34. However, lower DAT binding in the right caudate and right and 
left putamen at any post-baseline visit was found as a predictor of ICB15.  
On uncorrected analysis of our follow-up MRI scans, there was an increased 
atrophy rate in the anterior limb of the left internal capsule adjacent to the left 
caudate nucleus in PD-ICB. The anterior limb of the internal capsule includes 
fibers connecting the prefrontal and the anterior cingulate cortex35 and it has 
been successfully targeted for deep brain stimulation of obsessive-compulsive 
disorder. Although this finding could link ICB to structural alterations within 
fronto-limbic connections, it only arose as part of a more lenient statistical 
analysis and clearly needs to be judged in this light.  
It is important to acknowledge some methodological limitations. The presence 
of ICB was identified only by means of the QUIP, which was designed as a 
screening instrument with high sensitivity (94%) and lower specificity (72%). 
Therefore, we cannot exclude false positives or non-clinically relevant ICB17. 
The disease duration in the PD-no-ICB was longer as we selected the last 
available follow-up in this cohort. Our methodological approach was similar to 
a previous study on incident ICB from the PPMI cohort15 and allowed us 
including a sample of PD-no-ICB with evidence of absent ICB for the longest 
time possible. Indeed one could argue that this strengthens our assumption 
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that those patients in the no-ICB group were truly different from those who 
developed ICB, rather than it simply being an artefact of less opportunity, in 
terms of disease duration, to develop ICD. We also acknowledge that 
morphological features predicting ICB could be present in PD at diagnosis, 
but different image acquisitions or processing methods are needed to detect 
them. A weakness of the PPMI dataset is the presence of different scanning 
acquisition methodologies which we sought to overcome by specifying strict 
criteria for the imaging we did use. However, this had the consequence of 
reducing the numbers of subjects available for imaging analysis. A strategy for 
future studies would be to acquire quantitative MRI acquisitions, which can be 
used to look for changes in tissue properties at a microstructural level and 
identify structures that cannot be seen using conventional MRI, such as 
brainstem and thalamic nuclei36. 
Our work suggests that RBD, more severe anxiety and worse autonomic and 
cognitive function are able to predict future development of ICB in a de novo 
PD population. Structural imaging of the sort we had available cannot predict 
risk of development of ICB. Given the major impact of ICB on patients’ and 
caregivers’ quality of life, it is critical to identify at-risk individuals to support 
more tailored prescribing decisions, intensity of follow up and advice to 
patients and their families.  
 
ACKNOWLEDGEMENTS 
Data used in the preparation of this article were obtained from the Parkinson’s 
Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For 
up-to-date information on the study, visit www.ppmi-info.org. PPMI – a public-
private partnership – is funded by the Michael J. Fox Foundation for 
Parkinson’s Research and funding partners, including AbbVie, Avid, Biogen, 
Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, 
Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, 
Servier, Teva, and UCB. This study was not supported by additional funding.






TABLE 1: Baseline cognitive, psychiatric and non-motor symptoms in 
healthy controls (HC) and in Parkinson’s disease (PD)  
 
Abbreviations: GDS: Geriatric depression scale; HVLT: Hopkins verbal 
learning test; MoCA: Montreal cognitive assessment; * RBDSQ = REM Sleep 
Behavior Disorder Questionnaire (Yes = < 5, No ≥ 5); SCOPA-AUT: Scales 
for Outcomes in Parkinson's disease – Autonomic; STAI: State-trait anxiety 















Age 62.49.3 61.59.0 0.6 
Education level 15.43.0 15.52.9 0.9 
Gender (males/females) 58/26 30/12 0.8  
MoCA  27.82.9 2821.2 0.8 
Symbol Digit Modalities Test 41.710.5 49.011.3 0.003 
HVLT-R free recall 24.55.5 25.94.8 0.1 
HVLT-R recognition 
discrimination 
22.37.1 24.16.3 0.2 
Phonemic fluency  13.44.4 13.24.6 0.4 
Benton Judgement of Line 
Orientation 
13.91.9 13.61.5 0.2 
Letter-Number Sequencing 10.42.7 11.32.6 0.2 
Semantic fluency  48.011.6 51.110.1 0.2 
STAI-state 33.710.3 27.57.4 0.001 
STAI-trait 33.210.0 28.26.4 0.007 
STAI-total 66.919.4 55.713.3 0.001 
GDS 2.62.6 1.32.5 <0.0001 
UPSIT 21.48.9 343.6 <0.0001 
SCOPA_AUT 9.66.4 5.43.4 <0.0001 












TABLE 2: Baseline cognitive, psychiatric and non-motor symptoms in 
Parkinson’s disease (PD) with (PD-ICB) and without (PD-no-ICB) 
impulsive-compulsive behavior.  
 
Abbreviations: GDS: Geriatric depression scale; HVLT: Hopkins verbal 
learning test; MoCA: Montreal cognitive assessment; RBDSQ = REM Sleep 
Behavior Disorder Questionnaire (Yes = < 5, No ≥ 5); SCOPA-AUT: Scales 







Age (years) 62.69.6 62.29.1 0.8 
Gender (M/F) 30/12 28/14 0.6 
UPDRS-III 22.39.6 20.69.8 0.3 
H&Y 1.80.5 1.70.5 0.3 
Schwab & England (%) 94.46.1 93.56.7 0.5 
Disease duration from 
symptoms onset to baseline 
(months) 
19.913.5 21.723.9 0.6 
Disease duration from 
symptoms onset to follow-
up (months)* 
43.817.3 61.729.5 0.0001 
LEDD total (mg)* 353.3281.3 539.0342.9 0.01 
LEDD D-ag (mg)* 57.6296.7 53.687.1 0.9 
MoCA  27.42.1 28.31.6 0.03 
Symbol Digit Modalities Test 41.712.0 48.611.6 0.9 
HVLT-R free recall 24.2±5.7 24.8±5.4 0.6 
HVLT-R recognition 
discrimination 
21.57.8 23.36.2 0.3 
Phonemic fluency  12.94.6 13.84.2 0.3 
Benton Judgement of Line 
Orientation 
12.72.2 13.41.5 0.2 
Letter-Number Sequencing 10.33.1 10.52.2 0.6 
Semantic fluency  47.411.7 41.68.6 0.5 
STAI-state 36.210.6 31.19.5 0.02 
STAI-trait 35.49.6 30.810.0 0.01 
STAI-total 71.519.2 61.918.4 0.009 
GDS 2.82.24 2.53.0 0.2 
UPSIT 20.99.4 21.98.5 0.6 
SCOPA_AUT 11.67.6 7.43.8 0.004 
RBDSQ (Y/N) (%) 22/20 (52.3%) 12/30 (28.5%) 0.03 




inventory; UPSIT: University of Pennsylvania Smell Identification Test. H&Y: 
Hoehn and Yahr stage; D-Ag: dopamine agonists; LEDD: levodopa equivalent 
daily dose; UPDRS: Unified Parkinson’s disease Rating Scale. 
*At the time of QUIP conversion from negative to positive in PD-ICB, or at the 
last available follow-up visit in PD-no-ICB 
  




Table 3: Predictors of ICB development at PD diagnosis by 





p-value 95% C.I. 
    Lower Upper 
Age .013 .030 0.6 0.9 1.1 
MOCA  .310 .149 0.04* 1.0 1.8 
RBD (yes/no) .408 .544 0.4 0.5 4.4 
SCOPA-AUT -.131 .063 0.04* 0.7 0.9 
STAI total -.018 .015 0.2 0.9 1.0 
 
Dependent variable: ICB development (yes/no). Predictors: Age; MOCA at 
baseline; REM Sleep Behavior Disorder (yes/no); SCOPA-AUT (Scales for 
Outcomes in Parkinson's disease – Autonomic); STAI (State-trait anxiety 
inventory). * Significant values.   




LEGEND TO FIGURES 
Figure 1: The flow-chart show how the patients with de novo Parkinson’s 
disease with and without impulsive-compulsive behaviors (PD-ICB, PD-no-
ICB) were selected for this study from the PPMI original cohort. HC = healthy 
controls; QUIP = Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson’s Disease.  
 
Figure 2: Faster rate of grey and white matter atrophy, particularly in the 
bilateral hippocampi and striatum, in those with PD compared to HC (FWE P 
< 0.05).The average annualized rate of atrophy and thresholded t-statistic 
maps are shown, with FWE P<0.05 and uncorrected P < 0.001 labeled 
accordingly. Bottom row shows regions where the rate of atrophy was higher 
in PD compared to HC. 
. 
 
Figure 3: Small region of increased atrophy rate in the anterior limb of the left 
internal capsule adjacent to the head of the left caudate nucleus in PD-ICB 
compared to PD-no-ICB at follow-up (P < 0.001 uncorrected). 
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